Mesoblast Ltd. (NASDAQ:MESO) has earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the firm. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $9.67.

Separately, Zacks Investment Research raised Mesoblast from a “sell” rating to a “hold” rating in a research report on Tuesday, August 23rd.

Shares of Mesoblast (NASDAQ:MESO) opened at 4.65 on Wednesday. Mesoblast has a one year low of $3.50 and a one year high of $10.89. The company’s market cap is $351.42 million. The company has a 50 day moving average price of $4.31 and a 200 day moving average price of $5.17.

Several institutional investors have recently bought and sold shares of the company. Citigroup Inc. raised its position in Mesoblast by 659,900.0% in the second quarter. Citigroup Inc. now owns 33,000 shares of the company’s stock worth $131,000 after buying an additional 32,995 shares during the last quarter. Penbrook Management LLC acquired a new position in Mesoblast during the third quarter worth approximately $134,000. Finally, Princeton Capital Management Inc. raised its position in Mesoblast by 135.4% in the second quarter. Princeton Capital Management Inc. now owns 109,382 shares of the company’s stock worth $433,000 after buying an additional 62,915 shares during the last quarter. Institutional investors and hedge funds own 3.42% of the company’s stock.

Mesoblast Company Profile

5 Day Chart for NASDAQ:MESO

Receive News & Stock Ratings for Mesoblast Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Ltd. and related stocks with our FREE daily email newsletter.